Estrogen and progestin components of oral contraceptives: Relationship to vascular disease

Bruce R. Carr, Howard Ory

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Recently, new information has been published about: a) the relationship between combination oral contraceptives (OCs), estrogen dose, cigarette smoking, and the risk of myocardial infarction (MI) and stroke; and b) the effect of different progestins on the risk of venous thromboembolism (VTE). We review the epidemiologic data. Regardless of age, in the absence of smoking, use of sub-50 μg OCs is not associated with any meaningful increase in risk of MI or stroke. If the small, statistically nonsignificant elevations in risk for these diseases are assumed (for the sake of argument) to be causal, then the incidence of MI and stroke associated with use of OCs containing less than 50 μg ethinyl estradiol (EE) would be approximately 2 per 100,000 per year. For women less than 35 years of age who do not smoke or do not have a history of hypertension, the risk would be even lower. Any woman over the age of 35 who smokes should be advised to use a non estrogen or nonhormonal contraceptive. There are now two reports, from Jick et al. and Lewis at al., that demonstrate that the relative risk of MI is certainly no greater for users of OCs containing desogestrel or gestodene than for users of OCs containing older progestins. In fact, both show reduced relative risks for the newer progestins compared to the older ones. With respect to progestins, four recent epidemiologic studies have indicated a twofold increased risk of nonfatal VTE with use of OCs containing desogestrel or gestodene compared with levonorgestrel. A fifth report, which showed an increased relative risk for norgestimate, is based on use among only 19 cases and 31 controls and is not statistically significant. As the authors themselves caution and as subsequent follow-up analyses and editorials conclude, these studies do not provide evidence for a cause and-effect relationship between OCs containing desogestrel or gestodene, and VTE. The recommendation with respect to desogestrel and gestodene-containing OCs is that no change in prescribing practices is warranted for either current or new-start patients. There is a growing body of evidence demonstrating that OCs containing 30 or 35 μg of EE have lower risks of MI, stroke, and VTE than higher dose OCs. However, there is no epidemiologic study that demonstrates a greater risk of vascular events among women using OCs containing 30 or 35 μg EE compared with preparations containing 20 μg EE. Users of sub-50 μg OCs of any age have no clinically meaningful increase in incidence of MI or stroke compared with non-OC users. This is also true for smokers under the age of 35 years who use OCs. However, smokers over the age of 35 years who use OCs still have an unacceptably high incidence rate of MI and stroke and should not use combination OCs. Sub-50 μg OCs of all types are associated with a small excess risk of VTE, about 15 per 100,000 events per year. Until there is biologic explanation of the twofold greater risk of VTE in users of OCs containing desogestrel or gestodene compared with users of those containing older progestins, this association should lint be accepted as one of cause and effect.

Original languageEnglish (US)
Pages (from-to)267-272
Number of pages6
JournalContraception
Volume55
Issue number5
DOIs
StatePublished - May 1997

Fingerprint

Progestins
Oral Contraceptives
Vascular Diseases
Estrogens
Desogestrel
Venous Thromboembolism
Myocardial Infarction
Ethinyl Estradiol
Stroke
Contraceptive Agents
Smoke
Epidemiologic Studies
Incidence
Smoking
Levonorgestrel

Keywords

  • Coagulation system
  • Myocardial infarction
  • Oral contraception
  • Smoking
  • Stroke
  • Venous thromboembolism

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Estrogen and progestin components of oral contraceptives : Relationship to vascular disease. / Carr, Bruce R.; Ory, Howard.

In: Contraception, Vol. 55, No. 5, 05.1997, p. 267-272.

Research output: Contribution to journalArticle

@article{7ddf3e86c40641c59b6422f563b67795,
title = "Estrogen and progestin components of oral contraceptives: Relationship to vascular disease",
abstract = "Recently, new information has been published about: a) the relationship between combination oral contraceptives (OCs), estrogen dose, cigarette smoking, and the risk of myocardial infarction (MI) and stroke; and b) the effect of different progestins on the risk of venous thromboembolism (VTE). We review the epidemiologic data. Regardless of age, in the absence of smoking, use of sub-50 μg OCs is not associated with any meaningful increase in risk of MI or stroke. If the small, statistically nonsignificant elevations in risk for these diseases are assumed (for the sake of argument) to be causal, then the incidence of MI and stroke associated with use of OCs containing less than 50 μg ethinyl estradiol (EE) would be approximately 2 per 100,000 per year. For women less than 35 years of age who do not smoke or do not have a history of hypertension, the risk would be even lower. Any woman over the age of 35 who smokes should be advised to use a non estrogen or nonhormonal contraceptive. There are now two reports, from Jick et al. and Lewis at al., that demonstrate that the relative risk of MI is certainly no greater for users of OCs containing desogestrel or gestodene than for users of OCs containing older progestins. In fact, both show reduced relative risks for the newer progestins compared to the older ones. With respect to progestins, four recent epidemiologic studies have indicated a twofold increased risk of nonfatal VTE with use of OCs containing desogestrel or gestodene compared with levonorgestrel. A fifth report, which showed an increased relative risk for norgestimate, is based on use among only 19 cases and 31 controls and is not statistically significant. As the authors themselves caution and as subsequent follow-up analyses and editorials conclude, these studies do not provide evidence for a cause and-effect relationship between OCs containing desogestrel or gestodene, and VTE. The recommendation with respect to desogestrel and gestodene-containing OCs is that no change in prescribing practices is warranted for either current or new-start patients. There is a growing body of evidence demonstrating that OCs containing 30 or 35 μg of EE have lower risks of MI, stroke, and VTE than higher dose OCs. However, there is no epidemiologic study that demonstrates a greater risk of vascular events among women using OCs containing 30 or 35 μg EE compared with preparations containing 20 μg EE. Users of sub-50 μg OCs of any age have no clinically meaningful increase in incidence of MI or stroke compared with non-OC users. This is also true for smokers under the age of 35 years who use OCs. However, smokers over the age of 35 years who use OCs still have an unacceptably high incidence rate of MI and stroke and should not use combination OCs. Sub-50 μg OCs of all types are associated with a small excess risk of VTE, about 15 per 100,000 events per year. Until there is biologic explanation of the twofold greater risk of VTE in users of OCs containing desogestrel or gestodene compared with users of those containing older progestins, this association should lint be accepted as one of cause and effect.",
keywords = "Coagulation system, Myocardial infarction, Oral contraception, Smoking, Stroke, Venous thromboembolism",
author = "Carr, {Bruce R.} and Howard Ory",
year = "1997",
month = "5",
doi = "10.1016/S0010-7824(97)00029-2",
language = "English (US)",
volume = "55",
pages = "267--272",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Estrogen and progestin components of oral contraceptives

T2 - Relationship to vascular disease

AU - Carr, Bruce R.

AU - Ory, Howard

PY - 1997/5

Y1 - 1997/5

N2 - Recently, new information has been published about: a) the relationship between combination oral contraceptives (OCs), estrogen dose, cigarette smoking, and the risk of myocardial infarction (MI) and stroke; and b) the effect of different progestins on the risk of venous thromboembolism (VTE). We review the epidemiologic data. Regardless of age, in the absence of smoking, use of sub-50 μg OCs is not associated with any meaningful increase in risk of MI or stroke. If the small, statistically nonsignificant elevations in risk for these diseases are assumed (for the sake of argument) to be causal, then the incidence of MI and stroke associated with use of OCs containing less than 50 μg ethinyl estradiol (EE) would be approximately 2 per 100,000 per year. For women less than 35 years of age who do not smoke or do not have a history of hypertension, the risk would be even lower. Any woman over the age of 35 who smokes should be advised to use a non estrogen or nonhormonal contraceptive. There are now two reports, from Jick et al. and Lewis at al., that demonstrate that the relative risk of MI is certainly no greater for users of OCs containing desogestrel or gestodene than for users of OCs containing older progestins. In fact, both show reduced relative risks for the newer progestins compared to the older ones. With respect to progestins, four recent epidemiologic studies have indicated a twofold increased risk of nonfatal VTE with use of OCs containing desogestrel or gestodene compared with levonorgestrel. A fifth report, which showed an increased relative risk for norgestimate, is based on use among only 19 cases and 31 controls and is not statistically significant. As the authors themselves caution and as subsequent follow-up analyses and editorials conclude, these studies do not provide evidence for a cause and-effect relationship between OCs containing desogestrel or gestodene, and VTE. The recommendation with respect to desogestrel and gestodene-containing OCs is that no change in prescribing practices is warranted for either current or new-start patients. There is a growing body of evidence demonstrating that OCs containing 30 or 35 μg of EE have lower risks of MI, stroke, and VTE than higher dose OCs. However, there is no epidemiologic study that demonstrates a greater risk of vascular events among women using OCs containing 30 or 35 μg EE compared with preparations containing 20 μg EE. Users of sub-50 μg OCs of any age have no clinically meaningful increase in incidence of MI or stroke compared with non-OC users. This is also true for smokers under the age of 35 years who use OCs. However, smokers over the age of 35 years who use OCs still have an unacceptably high incidence rate of MI and stroke and should not use combination OCs. Sub-50 μg OCs of all types are associated with a small excess risk of VTE, about 15 per 100,000 events per year. Until there is biologic explanation of the twofold greater risk of VTE in users of OCs containing desogestrel or gestodene compared with users of those containing older progestins, this association should lint be accepted as one of cause and effect.

AB - Recently, new information has been published about: a) the relationship between combination oral contraceptives (OCs), estrogen dose, cigarette smoking, and the risk of myocardial infarction (MI) and stroke; and b) the effect of different progestins on the risk of venous thromboembolism (VTE). We review the epidemiologic data. Regardless of age, in the absence of smoking, use of sub-50 μg OCs is not associated with any meaningful increase in risk of MI or stroke. If the small, statistically nonsignificant elevations in risk for these diseases are assumed (for the sake of argument) to be causal, then the incidence of MI and stroke associated with use of OCs containing less than 50 μg ethinyl estradiol (EE) would be approximately 2 per 100,000 per year. For women less than 35 years of age who do not smoke or do not have a history of hypertension, the risk would be even lower. Any woman over the age of 35 who smokes should be advised to use a non estrogen or nonhormonal contraceptive. There are now two reports, from Jick et al. and Lewis at al., that demonstrate that the relative risk of MI is certainly no greater for users of OCs containing desogestrel or gestodene than for users of OCs containing older progestins. In fact, both show reduced relative risks for the newer progestins compared to the older ones. With respect to progestins, four recent epidemiologic studies have indicated a twofold increased risk of nonfatal VTE with use of OCs containing desogestrel or gestodene compared with levonorgestrel. A fifth report, which showed an increased relative risk for norgestimate, is based on use among only 19 cases and 31 controls and is not statistically significant. As the authors themselves caution and as subsequent follow-up analyses and editorials conclude, these studies do not provide evidence for a cause and-effect relationship between OCs containing desogestrel or gestodene, and VTE. The recommendation with respect to desogestrel and gestodene-containing OCs is that no change in prescribing practices is warranted for either current or new-start patients. There is a growing body of evidence demonstrating that OCs containing 30 or 35 μg of EE have lower risks of MI, stroke, and VTE than higher dose OCs. However, there is no epidemiologic study that demonstrates a greater risk of vascular events among women using OCs containing 30 or 35 μg EE compared with preparations containing 20 μg EE. Users of sub-50 μg OCs of any age have no clinically meaningful increase in incidence of MI or stroke compared with non-OC users. This is also true for smokers under the age of 35 years who use OCs. However, smokers over the age of 35 years who use OCs still have an unacceptably high incidence rate of MI and stroke and should not use combination OCs. Sub-50 μg OCs of all types are associated with a small excess risk of VTE, about 15 per 100,000 events per year. Until there is biologic explanation of the twofold greater risk of VTE in users of OCs containing desogestrel or gestodene compared with users of those containing older progestins, this association should lint be accepted as one of cause and effect.

KW - Coagulation system

KW - Myocardial infarction

KW - Oral contraception

KW - Smoking

KW - Stroke

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=0030750316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030750316&partnerID=8YFLogxK

U2 - 10.1016/S0010-7824(97)00029-2

DO - 10.1016/S0010-7824(97)00029-2

M3 - Article

C2 - 9220222

AN - SCOPUS:0030750316

VL - 55

SP - 267

EP - 272

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 5

ER -